Equities Analysts Offer Predictions for Repligen Co.’s Q2 2023 Earnings (NASDAQ:RGEN)

Posted by Defense World Staff on May 5th, 2023

Repligen Co. (NASDAQ:RGEN – Get Rating) – Equities research analysts at KeyCorp reduced their Q2 2023 earnings estimates for shares of Repligen in a research note issued to investors on Wednesday, May 3rd. KeyCorp analyst P. Knight now forecasts that the biotechnology company will earn $0.50 per share for the quarter, down from their previous forecast of $0.54. KeyCorp has a “Overweight” rating and a $240.00 price objective on the stock. The consensus estimate for Repligen’s current full-year earnings is $2.64 per share. KeyCorp also issued estimates for Repligen’s Q3 2023 earnings at $0.57 EPS, Q4 2023 earnings at $0.60 EPS and FY2023 earnings at $2.36 EPS.

A number of other analysts have also commented on the stock. StockNews.com began coverage on shares of Repligen in a research note on Thursday, March 16th. They issued a “sell” rating for the company. Benchmark cut their target price on shares of Repligen from $230.00 to $210.00 in a research report on Wednesday. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Repligen from $180.00 to $165.00 in a report on Wednesday. Craig Hallum lowered their target price on shares of Repligen from $220.00 to $207.00 in a report on Wednesday. Finally, Royal Bank of Canada reduced their price target on shares of Repligen from $170.00 to $157.00 in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average target price of $208.56.

Repligen Stock Performance

NASDAQ:RGEN opened at $157.23 on Thursday. The firm has a market cap of $8.75 billion, a P/E ratio of 53.30, a P/E/G ratio of 2.29 and a beta of 1.08. Repligen has a fifty-two week low of $137.21 and a fifty-two week high of $262.26. The firm has a 50-day simple moving average of $168.25 and a two-hundred day simple moving average of $175.22.

Repligen (NASDAQ:RGEN – Get Rating) last posted its earnings results on Tuesday, May 2nd. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.59 by $0.05. Repligen had a net margin of 23.20% and a return on equity of 10.31%. The firm had revenue of $182.70 million during the quarter, compared to analysts’ expectations of $181.43 million. During the same period last year, the company posted $0.92 EPS. The company’s quarterly revenue was down 11.5% compared to the same quarter last year.

Hedge Funds Weigh In On Repligen

Institutional investors have recently bought and sold shares of the company. Signaturefd LLC raised its position in Repligen by 13.8% in the third quarter. Signaturefd LLC now owns 469 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 57 shares in the last quarter. IFP Advisors Inc increased its holdings in Repligen by 34.3% during the 3rd quarter. IFP Advisors Inc now owns 227 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 58 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in Repligen by 0.9% during the 4th quarter. State of Alaska Department of Revenue now owns 7,226 shares of the biotechnology company’s stock worth $1,223,000 after purchasing an additional 65 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Repligen by 0.5% in the 3rd quarter. Arizona State Retirement System now owns 14,311 shares of the biotechnology company’s stock valued at $2,678,000 after acquiring an additional 67 shares during the last quarter. Finally, Commerce Bank increased its holdings in shares of Repligen by 5.7% in the 3rd quarter. Commerce Bank now owns 1,401 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 75 shares during the last quarter. 91.00% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

(Get Rating)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G.